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Background: Circulating neutrophil gelatinase-associated lipocalin (NGAL) concentration 
increases in cardiovascular disease, but the long-term prognostic value of NGAL 
concentration has not been evaluated in acute coronary syndrome (ACS). We examined the 
association between NGAL concentration and prognosis in patients with ACS after non-ST-
elevation myocardial infarction (NSTEMI) or STEMI. 
Methods and Results: NGAL concentration was measured in blood from 1121 consecutive 
ACS patients (30% women, mean age 65 years) on the first morning after admission. After 
adjustment for 14 variables, NGAL concentration predicted long-term (median 167 months) 
mortality (hazard ratio [HR] 1.33, 95% confidence interval [CI] 1.10–1.61, P = 0.003) for 
quartile (q) 4 of NGAL concentration. NGAL concentrations also predicted long-term 
mortality (HR = 1.63, 95% CI 1.31–2.03, P < 0.001, N=741) when adjusting for Global 
Registry of Acute Coronary Events (GRACE) score, left ventricular ejection fraction (LVEF), 
and pro-B-type natriuretic peptide (proBNP) and C-reactive protein (CRP) concentrations. 
With these adjustments, NGAL concentration predicted long-term mortality in NSTEMI 
patients (HR = 2.02, 95% CI 1.50–2.72, P < 0.001) but not in STEMI patients (HR = 1.32, 
95% CI 0.95–1.83, P = 0.100). In all patients, the combination of NGAL concentration and 
GRACE score yielded an HR of 5.56 (95% CI 4.37–7.06, P < 0.001) for q4/q4 for both 
variables. 
Conclusion: NGAL concentration in ACS is associated with long-term prognosis after 
adjustment for clinical confounders. Measuring circulating NGAL concentration may help to 
identify patients—particularly those with NSTEMI—needing closer follow-up after ACS. 




The course of patients with acute coronary syndrome (ACS), which can range from 
unstable angina/non-ST-elevation myocardial infarction (NSTEMI) to STEMI, varies 
considerably. Identification of patients with poor prognosis may help in the optimization of 
therapy and outcomes. The management of these patients has improved with the development 
of new biomarkers such as the troponin level, scoring systems such as the Global Registry of 
Acute Coronary Events (GRACE), and various inflammatory markers, in particular C-reactive 
protein (CRP). However, the ability to predict short- and long-term outcomes remains limited 
[1,2]. In this study, we sought to determine the predictive value of neutrophil gelatinase-
associated lipocalin (NGAL) concentration alone and in combination with the composite 
clinical GRACE score. 
NGAL was first isolated from neutrophil granules but was later shown to be produced 
by a wide range of cells and tissues [3]. In addition to being a sensitive marker of distal 
tubular damage in acute kidney injury, NGAL is upregulated in various inflammatory 
disorders such as inflammatory bowel disease, chronic obstructive pulmonary disease, and 
heart failure (HF) [4-8]. Increased serum NGAL concentration is found in patients with 
coronary artery disease (CAD) and is associated with disease instability and the number of 
vessels involved [9,10]. Strong NGAL expression has been reported within atherosclerotic 
carotid lesions associated with increased matrix metalloproteinase 9 (MMP-9) activity [11]. 
Although MMP-9 is genome-wide significantly associated with CAD [12], the role of NGAL 
as a marker and potential mediator of CAD is not clear. 
Previous studies have suggested that NGAL is a prognostic marker for cardiovascular 
(CV) disorders such as acute and chronic HF [10,13,14]. Considering its association with 
inflammation, matrix remodelling, renal function, and CAD severity, we hypothesized that 
NGAL concentration may also be a prognostic marker in ACS patients. To test this 
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hypothesis, we measured NGAL concentration in serum obtained from a large population of 
patients with ACS admitted to a Scandinavian university hospital, and we estimated its 
associations with long-term all-cause mortality in the entire population of ACS patients and in 
subgroups of STEMI and NSTEMI patients. We also estimated the predictive value of NGAL 
concentration compared with traditional risk factors and the composite GRACE risk score, 
and the relationships between NGAL concentration and MMP-9 and CRP concentrations. 
2. Methods 
2.1. Study design 
We used frozen serum samples from the ‘Prognosis and Risk in ACS in Sweden’ study 
(PRACSIS) [15,16]. Patients admitted to the coronary care unit at Sahlgrenska University 
Hospital, Gothenburg, Sweden, from September 1995 to March 2001 who were diagnosed 
with ACS were consecutively included to reflect the general ACS population treated at this 
centre. The diagnosis of ACS was based on chest pain and/or other symptoms suggestive of 
myocardial ischaemia in combination with ECG changes, biochemical markers of myocardial 
necrosis, or previously recognized CAD. The upper reference levels of biochemical markers 
at the time of inclusion were higher than today, and a large proportion of the patients 
diagnosed with unstable angina would have fulfilled the current criteria for NSTEMI. We 
have therefore included patients with unstable angina among the NSTEMI group in this 
report. The main exclusion criteria were age <18 or 80 years, non-CAD patients with a life 
expectancy <1 year, residence outside the hospital’s catchment area, unwillingness, or prior 
admission resulting in inclusion in the study. Clinical data were collected from hospital 
medical records and through an interview conducted by an experienced research nurse. The 
GRACE risk score for post-discharge death was calculated for each patient [17]. Survival 
confirmation and date of death were obtained from the Swedish National Population Registry, 
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which includes all residents of Sweden. All-cause mortality was studied during the long-term 
follow-up (167 months); i.e., from the index event until 1 January 2015. 
The study was approved by the Ethics Committee of Gothenburg University, and all 
patients provided informed consent [18]. 
2.2. Blood sampling 
Peripheral venous blood was obtained the first morning after admission. For NGAL 
measurement, blood was collected into sterile tubes without additives, allowed to clot at room 
temperature, and centrifuged (1200 g for 10 min) within 1 h. For high-sensitivity 
determination of other biomarkers, blood was collected in cold EDTA tubes and centrifuged 
(4 C, 2000 g for 15 min) within 1 hour, and the plasma was stored. Serum and plasma 
samples were kept at –80 C. 
2.3. Biochemical analyses 
Serum NGAL concentration was measured by enzyme immunoassay (R&D Systems, 
Minneapolis, MN) with a sensitivity of 0.04 ng/mL. The intra- and inter-assay variances were 
<5% and <10%, respectively. Although storage time differed (samples were collected 
between 1995 and 2001, and analysed in 2011), NGAL has been shown to be stable when 
stored at –80 C, and its concentration is influenced only slightly by multiple thawing cycles 
[19]. The range from the minimum detectable concentration to the upper limit (without 
dilution) was 0.156–10 ng/mL for NGAL. 
Serum troponin T (TnT) and creatine kinase (CK-MB) concentrations were measured 
on a modular platform (Roche Diagnostics, Mannheim, Germany). Pro-B-type natriuretic 
peptide (BNP)3–108 (proBNP), high-sensitivity CRP (hsCRP), troponin I (TnI), and MMP-9 
concentrations were measured using immunofluorescence assays calibrated with spiked 
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plasma (Biosite Inc., San Diego, CA). The ranges from the minimum detectable concentration 
to the upper limit (without dilution) were 0.156–10 ng/mL for proBNP and 0.3–100 mg/L for 
hsCRP. All samples were tested in duplicate in a blinded fashion. Serum total cholesterol, low 
density lipoprotein (LDL) and creatinine concentrations were measured by routine laboratory 
methods. Estimated glomerular filtration rate (eGFR) was calculated using the Cockcroft–
Gault formula [(140-age x weight(kg)/serum creatinine (µmol/L)] multiplied by a constant of 
1.23 in men and 1.04 in women. 
2.4. Echocardiography 
An experienced investigator performed an echocardiographic investigation within 5 
days of hospital admission. The biplane left ventricular ejection fraction (LVEF) was 
calculated using the disc summation method, and tracings were checked for accuracy in 
motion mode [20]. 
2.5. Statistical analysis 
Categorical variables are reported as percentages, and continuous variables as median 
values with interquartile ranges (25th–75th percentile) or mean and standard deviation (SD). 
The associations between NGAL concentration and baseline demographic variables and CV 
risk factors were tested using the Mann–Whitney U test to compare patients with and without 
a specific characteristic. Spearman rank correlational analysis was used to test the associations 
between continuous variables and NGAL concentration. Actual individual NGAL 
concentration was used to calculate the P-values shown in Table 1. 
The assumption of linearity for NGAL concentrations was checked by entering the 
squared transformation into the models and studying the change in –2 log likelihood. This 
assumption was violated even after transformation of NGAL concentrations using the natural 
logarithm. We decided to use NGAL concentration dichotomised at the 75th percentile in all 
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analyses. Cox proportional-hazard regression was used to calculate the crude and adjusted HR 
for NGAL q4 compared with q1–3 for all deaths.  
Analysis of long-term all-cause mortality included adjustments in two steps. First, we 
analysed the effect on the hazard ratio (HR) for the fourth quartile (q4) of NGAL versus q1–3 
after adjusting for each baseline characteristic (Table 1) separately, both with and without age 
adjustment. Variables that altered the HR by 3.0%, with or without age adjustment, were 
defined as confounders and used in the final multivariable model. Model 1) included only 
confounders with <3% missing data and model 2) included all confounders. 
Due to the amount of missing data for some of the variables, we also performed analysis 
using multiple imputation of missing data. Missing data were assumed to occur at random 
(MAR) and 50 imputed data sets were generated with the Markov Chain Monte Carlo 
(MCMC) method and the expectation-maximization (EM) algorithm. Rubin´s rules were used 
when pooling the results from the imputed data sets.   
A second multivariable analysis included three adjustments: 1) no adjustment (n = 
1121); 2) adjustment for GRACE score (based on age, history of HF, history of myocardial 
infarction (MI), heart rate, systolic blood pressure, ST-segment depression on admission 
ECG, elevated biomarkers of myocardial necrosis, baseline creatinine concentration, and no 
in-hospital percutaneous coronary intervention (PCI) (n = 1118); and 3) as in 2) but with 
hsCRP and proBNP concentrations, and LVEF in a patient subgroup with this additional 
information (n = 741). 
To analyse the added usefulness of NGAL concentration in clinical assessment, we 
calculated the ‘category-less’ net reclassification improvement (NRI), integrated 
discrimination improvement (IDI), and difference in the area under the receiver-operating 
characteristic curve (AUC) after adding NGAL concentration to the models for all-cause 
mortality at 165 months (from last patient inclusion to 1 January 2015). 
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To visualize the relationship between NGAL quartiles and long-term prognosis, 
Kaplan–Meier plots were generated, and the log-rank test was used to compare the resulting 
curves. 
Median follow-up was calculated using the observed follow-up times for all patients 
from inclusion to the date of death for those who died or to the date of last follow-up. 
All tests were two-sided; P-values < 0.05 were considered significant. All statistical 
analyses were performed using SAS (version 9.3; SAS Institute, Cary, NC). 
3. Results 
3.1. Baseline characteristics 
NGAL concentration was measured in 1121 patients (30% women, mean age 65 years) 
from day 1; 43% received a final diagnosis of STEMI and 57% of NSTEMI. The median 
(25th, 75th percentile) NGAL concentrations were 298 (220, 425) and 281 (209, 388) g/L, 
respectively (P = 0.01). Table 1 shows the characteristics at admission according to NGAL 
quartiles. The percentage of STEMI patients was highest in the fourth quartile. Patients with a 
higher NGAL concentration at baseline were older, less likely to be female, and more likely 
to smoke, and had higher concentrations of CK-MB, TnT, proBNP, and hsCRP, and 
leukocyte count. They also had lower eGFR and total cholesterol and low-density lipoprotein 
(LDL) cholesterol concentrations. At admission, those with a higher NGAL level were also 
more likely to have Killip class II–IV, lower LVEF, and higher GRACE score. Patients with a 
higher NGAL concentration were more likely to have a history of MI, HF, diabetes, or 
hypertension. The association between NGAL concentration and PCI was inverse and 
reflected mainly secondary PCI undertaken after blood sampling; primary PCI was not 
associated with NGAL concentration. 
After including all variables univariately associated with NGAL concentration in a 
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linear multivariable stepwise regression analysis (Table S1), eGFR, female sex, total 
cholesterol concentration, and ‘not primary PCI’ remained significantly inversely associated 
with NGAL concentration, whereas hsCRP concentration, smoking, and diabetes showed a 
significant direct association. These variables explained ~20% of the variation in NGAL 
concentration. 
3.2. NGAL concentration and long-term prognosis 
In the univariate analysis, long-term all-cause mortality was nearly twofold higher in 
patients in NGAL q4 compared with q1–3 (HR  1.93, 95% confidence interval [CI] 1.63–
2.28, P < 0.001). 
The influence on this relationship of each baseline characteristic in Table 1 was tested 
individually (results shown in Table S2). Factors affecting the relationship between long-term 
mortality and HR of NGAL q4 vs q1–3 by 3% (with or without adjustment for age) were 
used for multivariable adjustment. When including patients with nearly complete data (N = 
1086), these were age, sex, previous MI, previous angina, previous HF, previous diabetes, 
current smoker, lipid-lowering drugs, systolic blood pressure <100 mm Hg at admission, 
eGFR, max Killip class II–IV, thrombolysis, primary PCI, and other PCI. After adjusting for 
these variables, the HR for NGAL q4 vs q1–3 was 1.33 (95% CI 1.10–1.61, P = 0.003) (Table 
S3 upper). 
Without consideration of data completeness, proBNP, hsCRP, total cholesterol, and 
ln(LDL cholesterol) concentrations, and LVEF were added to the model because they also 
influenced the relationship of NGAL with mortality by 3%. The adjusted HR for NGAL q4 
vs q1-3 was 1.50 (95% CI 1.16–1.94, P = 0.002) (N = 639) (Table S3 lower). After applying 
multiple imputation analysis to handle missing data, the relationship remained significant: HR 
= 1.31 (95% CI 1.08–1.58, P = 0.006). Evaluation of the interactions between NGAL (q1–3 
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vs. q4) and each variable in Table 1 related to long-term mortality showed that these factors 
interacted significantly with NGAL concentration (Table S4): high (q4) leucocyte count 
(stronger effect when high NGAL); Killip class II–IV at admission or at any time before 
discharge (stronger effect when low NGAL); and low LVEF (q1) (greater effect when low 
NGAL). After adjusting for age, thrombolysis also had a stronger effect on mortality in 
patients with high NGAL concentration. 
3.3. Survival plots of long-term all-cause mortality 
Kaplan–Meier estimates of long-term all-cause mortality according to NGAL quartiles 
are shown in Fig. 1 (upper panel). The corresponding estimates of long-term all-cause 
mortality according to NGAL quartiles in STEMI (middle panel) and NSTEMI (lower panel) 
patients are also shown in Fig. 1. 
3.4. GRACE score combined with NGAL concentration 
To test the prognostic value of clinical data combined with NGAL concentration, we 
calculated the GRACE risk score. First, we tested the influence of this composite score on the 
relationship between NGAL concentration and all-cause mortality. As mentioned above and 
shown in Fig. 2, NGAL q4 had a 93% higher mortality risk than q1–3. Adjusting for the 
GRACE score reduced the HR of NGAL q4 vs q1–3 to 1.55 (95% CI 1.30–1.84). In the 741 
patients with data available for LVEF and proBNP and hsCRP concentrations, NGAL q4 
retained a 63% increased risk (P < 0.001) (Fig. 2 upper panel). Adding NGAL concentration 
to the full model of GRACE score, LVEF, and proBNP and hsCRP concentrations yielded an 
NRI of 0.35 (P < 0.001) and IDI of 0.013 (P = 0.002). The change in AUC was not significant 
(0.819 vs. 0.813, P = 0.10). 
Separate analyses of STEMI and NSTEMI patients are shown in Fig. 1 (survival plots) 
and Fig. 2 (univariate and adjusted HRs). In STEMI patients, after adjustment for GRACE 
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score, LVEF, and hsCRP and proBNP concentrations, the adjusted HR for the association of 
NGAL concentration with all-cause long-term mortality was 1.32 (95% CI 0.95–1.83, P = 
0.10). In NSTEMI patients the corresponding association was significant, with HR 2.02 (95% 
CI 1.50–2.72, P < 0.001). 
We next evaluated the combination of GRACE score and NGAL in all patients. The 
survival plot in Fig. 3 shows that this combination was a powerful prognostic indicator. The 
HRs for q4 NGAL/q4 GRACE were 1.49 (95% CI 1.15–1.93, P = 0.002) relative to q1–3 
NGAL/q4 GRACE; 3.11 (95% CI 2.34–4.12, P < 0.001) relative to q4 NGAL/q1–3 GRACE; 
and 5.56 (95% CI 4.37–7.06, P < 0.001) relative to q1–3 NGAL/q1–3 GRACE. The AUC for 
long-term all-cause mortality was 0.674 (95% CI 0.650–0.698) for GRACE q4. Adding 
NGAL concentration increased the AUC to 0.710 (95% CI 0.682–0.737) relative to GRACE 
alone (P < 0.001). 
3.5. NGAL, MMP-9, and hsCRP concentrations 
MMP-9 concentration correlated with NGAL concentration (r = 0.27, P < 0.0001, N = 
928). However, MMP-9 concentration was not a significant predictor of long-term mortality 
and did not add predictive value to NGAL concentration alone. Univariate analysis of MMP-9 
concentration produced HRs of 1.04 (95% CI 0.85–1.28, P = 0.70) for q4 vs q1–3 and 1.01 
(95% CI 0.82–1.23, P = 0.96) for q2–4 vs q1. 
We have previously reported that hsCRP concentration has prognostic value in this 
study population [21]. In the current study, we evaluated whether hsCRP had additive value 
when combined with NGAL concentration or GRACE score. Supplementary Table S5 shows 
the results for the prediction of long-term mortality in 938 patients with available data for 
NGAL and hsCRP concentrations and GRACE score. NGAL concentration and GRACE 
score combined yielded an HR of 7.46 (95% CI 5.64–9.88, P < 0.0001) for q4 vs q1–3. 
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hsCRP concentration and GRACE score combined yielded an HR of 5.74 (95% CI 4.33–7.61, 
P < 0.0001) for q4/q4 vs q1–3/q1–3. NGAL and hsCRP concentrations combined yielded an 
HR of 2.80 (95% CI 2.13–3.67, P < 0.0001) for q4/q4 vs q1–3/q1–3. 
4. Discussion 
In this prospective study, NGAL concentration was strongly and significantly associated 
with all-cause mortality during long-term follow-up in ACS patients. Surprisingly, the 
association was stronger in NSTEMI than in STEMI patients. NGAL concentration is a 
reliable marker of kidney injury [4] and, in this ACS population, correlated strongly with 
eGFR. However, its association with the outcome was not explained by kidney function or 
other known prognostic markers such as hsCRP and proBNP concentrations, LVEF, or 
GRACE score. MMP-9 concentration was also not an explanatory factor despite its 
correlation with NGAL concentration. Our findings suggest that NGAL concentration 
warrants further study as a prognostic biomarker in ACS, especially NSTEMI. 
NGAL concentration predicts all-cause mortality and major adverse cardiac events 
(MACE) in the general population [22] and MACE following coronary angiography [23]. In 
patients with PCI-treated STEMI, increased NGAL concentration is associated with risk of 
all-cause mortality or major CV events [24, 25]. However, data on long-term prognosis in the 
broad spectrum of ACS patients, as in our study, and in NSTEMI patients, are lacking. We 
included a larger study population and recorded more deaths during a longer follow-up than 
earlier STEMI studies [24,25]. The pathophysiology and degree of inflammation differ 
between types of ACS. Our findings support the recent view that different pathogenic 
mechanisms may underlie NSTEMI and STEMI [26]. 
NGAL concentration may be useful clinically for risk stratification when determining 
the long-term prognosis of ACS patients. This is supported by the highly significant NRI, 
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which suggests that reclassifying patients according to NGAL concentration may significantly 
improve risk classification. By contrast, adding the NGAL concentration to the model of 
GRACE score, LVEF, and hsCRP and proBNP concentrations did not significantly increase 
the AUC, possibly because the AUC  was already ~0.80 and, therefore, adding other strong 
predictors to the model would have only a modest effect [2]. If so, this does not necessarily 
preclude the potential clinical value of NGAL concentration as a prognostic marker of ACS. 
Consistent with this idea, in the group with both high GRACE score and high NGAL 
concentration (q4/q4) compared with the q1–3 group, the AUC value increased significantly 
after adding NGAL compared with GRACE alone. This suggests that combining these 
variables may yield important information. 
In addition to CV disease, in kidney disorders, which are known to be associated with 
NGAL concentration, urinary and circulating NGAL concentrations increase before the 
creatinine concentration increases. NGAL concentration also increases in other inflammatory 
conditions and cancer [4,7,27,28]. Although NGAL concentration was significantly 
associated with eGFR, adjusting for eGFR directly in the multivariable model did not change 
the association between NGAL concentration and long-term outcome. This suggests that the 
prognostic value of NGAL concentration did not simply reflect kidney function in these ACS 
patients. 
The strong association between NGAL concentration and adverse outcomes in ACS 
patients may have several explanations. First, NGAL concentration reflects various processes 
that influence prognosis in ACS patients, such as impaired kidney function and inflammation 
(e.g., neutrophil granulocyte activation). Second, NGAL forms complexes with MMP-9 and, 
in this configuration, MMP-9 remains functionally active for longer than when not complexed 
with NGAL. NGAL and MMP-9 concentrations correlated in our study; strong associations 
between the two have been found in plaques at risk of rupture and between MMP-9 activity 
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and NGAL concentration [11]. Therefore, in addition to its role as a marker of active 
atherosclerotic disease, NGAL may also play a role in plaque progression and destabilization 
through matrix degradation, which would predispose to further CV events. Third, strong 
NGAL expression in atherosclerotic lesions and marked myocardial upregulation of NGAL in 
experimental MI [6] suggest that the association of NGAL with adverse outcomes in ACS 
patients reflects the role of the myocardium and atherosclerotic lesions as cellular sources of 
circulating NGAL during ACS. 
The pathophysiology and degree of inflammation vary between types of ACS [26]. The 
stronger association between NGAL concentration and mortality in NSTEMI patients may 
provide a clue about the role and source of NGAL in ACS. One possible interpretation is that 
NGAL in NSTEMI patients primarily reflects plaque inflammation and/or erosion, in 
accordance with the more serious CAD in NSTEMI [29,30]. Neutrophils constitute an 
important cellular source of NGAL, which may increase MMP-9 activity by inhibiting its 
degradation. Given the postulated role of neutrophils and MMPs in plaque erosion, NGAL 
may be both a marker of pathways activated during NSTEMI and a mediator of NSTEMI 
development. 
4.1. Limitations 
The long-term follow-up of these patients means that, although a large proportion of our 
patients were treated according to current treatment guidelines for the management of ACS 
(http://dx.doi.org/10.1093/eurheartj/ehv320), the results might differ from those obtained 
from a cohort initiated more recently. The lack of data on high-sensitivity TnT concentration 
is a limitation. Another limitation is that some covariates did not have complete data; 
however, the association of NGAL concentration with outcome remained significant after 
multiple imputation analysis. 




Serum NGAL concentration at admission was strongly associated with all-cause 
mortality during long-term follow-up in a large population of ACS patients. The association 
was strongest in NSTEMI patients. Our findings suggest that NGAL concentration may be a 
useful biomarker for risk stratification in ACS patients, especially in NSTEMI patients, and 
may provide additional information beyond that of traditional biomarkers (e.g., hsCRP, 
proBNP, and troponin concentrations) in these patients. Further mechanistic studies are 
needed to elucidate the role of NGAL in atherosclerotic disorders. 
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Fig. 1. Kaplan–Meier estimates of long-term all-cause mortality in all patients according to 
NGAL quartiles for the entire study group (upper panel), for patients with ST-elevation 
myocardial infarction (middle panel), and patients with non-ST-elevation myocardial 
infarction (lower panel). 
 
Fig. 2. Association between the top NGAL quartile (q4) and long-term prognosis for all-cause 
mortality (n = number of events/total number of patients). 
* adjusted for GRACE score, and **adjusted for GRACE score, pro-B-type natriuretic 
peptide and high sensitivity C-reactive protein concentrations, and left ventricular ejection 
fraction. 
 
Fig. 3. Kaplan–Meier estimates for the entire study population according to various 
combinations of NGAL concentration and GRACE score. The effects on mortality of various 
combinations of high (q4) and low (q1–3) NGAL concentration and GRACE score are shown. 
 




Baseline characteristics of the study population (N = 1121) according to NGAL quartiles. 
 NGAL q1 
<215 g/L 
(n = 280) 
NGAL q2 
215–289 g/L 
(n = 282) 
NGAL q3 
290–403 g/L 
(n = 279) 
NGAL q4 
>403 g/L 
(n = 280) 
P-value* 
Age (years)  63 (56, 71) 66 (57, 74) 66 (58, 73) 69 (60, 74) <0.001 
Female (%) 36 36 24 25 <0.001 
Previous MI (%) 19 20 24 24 0.04 
Previous angina (%) 41 46 46 47 0.16 
Previous HF (%) 5 5 8 11 <0.001 
Previous diabetes (%) 17 15 15 22 0.03 
Previous hypertension (%) 36 40 41 44 0.02 
Previous hypercholesterolaemia (%) 29 32 29 23 0.07 
Current smoker (%) 25 [1] 30 [1] 33 [1] 37 [1] 0.005 
Lipid-lowering drug (%) 14 18 12 11 0.12 
STEMI (%) 39 41 43 48 0.01 
ST elevation at admission (%) 35 39 41 43 0.02 
ST depression at admission (%) 10 11 11 14 0.06 
Q-wave at admission (%) 9 10 12 17 0.001 
Systolic BP < 100 mmHg at admission (%) 2 2 2 4 0.25 
Heart rate (beats/min)  70 (60, 84) 70 (60, 84) 77 (65, 88) 72 (61, 90) 0.004 
CK-MB max (g/L) 50 (8, 177) 48 (8, 161) 57 (8, 172) 70 (14, 232) 0.009 
TnT max (g/L)  0.8 (0.1, 2.4) [2] 0.7 (0.1, 3.9) [2] 1.0 (0.1, 4.1) [2] 1.5 (0.1, 6.9) [2] <0.001 
TnI at admission (ng/L) 4190 (360, 14740) [3] 4280 (170, 17250) [3] 5410 (540, 17450) [3] 7410 (720, 18940) [3] 0.01 
Estimated GFR (mL/min/1.73 m2) 70 (58, 87) [1] 65 (54, 84) [1] 66 (54, 81) [1] 57 (43, 74) [1] <0.001 
ProBNP (pg/mL) 1551 (550, 2941) [2] 1576 (526, 3000) [2] 1763 (748, 3393) [2] 2222 (1025, 3976) [2] <0.001 
hsCRP (mg/dL) 8.7 (3.2, 19.4) [2] 11.2 (4.3, 25.8) [2] 17.4 (7.8, 50.9) [2] 23.2 (10.3, 64.3) [3] <0.001 
Leukocytes (103/L) 8.0 (6.1, 9.5) [1] 8.4 (6.6, 10.4) [1] 9.2 (7.6, 11.6) [1] 9.9 (8.0, 12.4) [1] <0.001 
Total cholesterol (mmol/L) 5.6 (4.8, 6.4) [1] 5.4 (4.6, 6.1) [2] 5.2 (4.6, 6.1) [2] 5.2 (4.3, 6.0) [2] <0.001 
LDL cholesterol (mmol/L) 3.6 (2.9, 4.3) [2] 3.4 (2.8, 4.1) [2] 3.5 (2.8, 4.1) [2] 3.2 (2.5, 4.0) [2] 0.003 
BMI (kg/m2) 25.9 (23.5, 28.4) [1] 25.9 (23.7, 29.4) [1] 25.7 (23.7, 28.3) [1] 25.4 (23.4, 27.8) [1] 0.31 
Killip class II–IV (%) 2 2 9 11 <0.001 
Max Killip class II–IV (%) 11 11 19 29 <0.001 
Thrombolysis (%) 16 17 18 22 0.02 
Primary PCI (%) 13 16 17 15 0.69 
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Other PCI (%) 26 22 16 13 <0.001 
CABG (%) 9 10 10 8 0.42 
No thrombolysis or revascularization (%) 42 40 44 48 0.06 
LVEF (%) 55 (49, 63) [2] 55 (48, 61) [2] 54 (44, 60) [2] 50 (41, 60) [2] <0.001 
GRACE (risk score) 102 (83, 118) 104 (88, 123) 110 (92, 128) 118 (96, 137) <0.001 
Continuous variables are reported as median (25th, 75th percentile) 
* Actual NGAL value used in P-value calculations. 
[1] 1–5% missing; [2] 5–25% missing; [3] >25% missing. MI, myocardial infarction; HF, heart failure; STEMI, ST elevation myocardial infarction; CK-MB, creatine kinase MB 
isoform; TnI, troponin I; TnT, troponin T; GFR, glomerular filtration rate; ProBNP, pro-brain natriuretic protein; hsCRP, high sensitivity C-reactive protein; LDL, low-
density lipoprotein; BMI, body mass index; PCI, percutaneous coronary intervention, CABG, coronary aortic bypass grafting; LVEF, left ventricular ejection fraction; 
GRACE, Global Registry of Acute Coronary Events. 
 

















































Stepwise regression model of baseline characteristics associated with the NGAL concentration. 
Variable Beta coefficient P-value 
ln(eGFR) –0.43301 <0.0001 
Female sex –0.19685 <0.0001 
Current smoker 0.13996 <0.0001 
ln(total cholesterol) –0.13570 <0.0241 
PCI, not primary –0.09785 <0.0058 
Previous diabetes 0.08402 <0.0325 
Ln (hsCRP) 0.07641 <0.0001 
 
eGFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention; hsCRP, high-
sensitivity C-reactive protein. 




Comparisons of the relationships between NGAL concentration and all-cause mortality in q4 vs q1–3 during 
long-term follow-up. 
_______________________________________________________________________________________ 
   Covariate  Age  Age + covariate 
  Unadjusted adjusted  adjusted  adjusted 
       
Age n = 1121 1.93 (1.63─2.28) 1.73 (1.46─2.05)  ------------------- ------------------- 
Sex n = 1121 1.93 (1.63─2.28) 1.95 (1.65─2.31)  1.73 (1.46─2.05)  1.70 (1.44─2.02) 
Previous MI n = 1121 1.93 (1.63─2.28) 1.96 (1.65─2.32)  1.73 (1.46─2.05)  1.75 (1.48─2.08) 
Previous angina n = 1121 1.93 (1.63─2.28) 1.96 (1.66─2.32)  1.73 (1.46─2.05)  1.74 (1.46─2.06) 
Previous HF n = 1121 1.93 (1.63─2.28) 1.88 (1.59─2.23)  1.73 (1.46─2.05)  1.67 (1.41─1.98) 
Previous diabetes n = 1121 1.93 (1.63─2.28) 1.89 (1.59─2.24)  1.73 (1.46─2.05)  1.69 (1.42─2.00) 
Previous hypertension n = 1120 1.92 (1.62─2.27) 1.91 (1.61─2.26)  1.72 (1.45─2.04)  1.72 (1.45─2.04) 
Previous hypercholesterolemia n = 1120 1.93 (1.63─2.29) 1.93 (1.63─2.29)  1.73 (1.46─2.05)  1.75 (1.48─2.07) 
Current smoker n = 1103 1.91 (1.61─2.27) 1.94 (1.64─2.31)  1.71 (1.44─2.03)  1.67 (1.40─1.99) 
Lipid-lowering drug n = 1121 1.93 (1.63─2.28) 1.96 (1.65─2.32)  1.73 (1.46─2.05)  1.75 (1.48─2.07) 
STEMI n = 1121 1.93 (1.63─2.28) 1.96 (1.65─2.32)  1.73 (1.46─2.05)  1.75 (1.47─2.08) 
NSTEMI n = 1121 1.93 (1.63─2.28) 1.94 (1.64─2.29)  1.73 (1.46─2.05)  1.74 (1.46─2.06) 
Adm ST elevation n = 1119 1.93 (1.63─2.28) 1.95 (1.65─2.31)  1.73 (1.46─2.05)  1.75 (1.47─2.07) 
Adm ST depression n = 1119 1.93 (1.63─2.28) 1.91 (1.62─2.27)  1.73 (1.46─2.05)  1.72 (1.45─2.03) 
Q-wave at admission n = 1119 1.93 (1.63─2.28) 1.91 (1.61─2.26)  1.73 (1.46─2.05)  1.71 (1.44─2.03) 
Adm systolic BP <100 n = 1121 1.93 (1.63─2.28) 1.92 (1.25─2.27)  1.73 (1.46─2.05)  1.70 (1.44─2.02) 
Adm heart rate n = 1120 1.93 (1.63─2.28) 1.92 (1.62─2.28)  1.72 (1.46─2.04)  1.70 (1.44─2.02) 
CK-MB max n = 1121 1.93 (1.63─2.28) 1.94 (1.63─2.30)  1.73 (1.46─2.05)  1.72 (1.45─2.04) 
TnI n = 801 2.14 (1.74─2.62) 2.15 (1.75─2.64)  1.94 (1.58─2.38)  1.93 (1.57─2.37) 
TnT max n = 931 2.06 (1.70─2.48) 2.03 (1.68─2.46)  1.89 (1.56─2.28)  1.87 (1.54─2.26) 
Estimated GFR n = 1104 1.89 (1.60─2.25) 1.53 (1.28─1.82)  1.70 (1.43─2.01)  1.61 (1.35─1.92) 
ProBNP n = 928 2.13 (1.76─2.58) 1.95 (1.61─2.36)  1.98 (1.64─2.40)  1.89 (1.56─2.29) 
hsCRP n = 941 2.12 (1.75─2.56) 1.97 (1.62─2.39)  1.98 (1.63─2.40)  1.84 (1.52─2.24) 
Leukocytes n = 1079 1.94 (1.63─2.31) 1.92 (1.62─2.28)  1.72 (1.44─2.04)  1.70 (1.43─2.03) 
Total cholesterol n = 1063 1.93 (1.62─2.30) 1.87 (1.57─2.23)  1.75 (1.47─2.09)  1.72 (1.44─2.05) 
LDL cholesterol n = 956 1.88 (1.57─2.27) 1.84 (1.52─2.21) 1.76 (1.46─2.12)  1.73 (1.44─2.08) 
BMI n = 1092 1.89 (1.59─2.24) 1.88 (1.58─2.23)  1.69 (1.42─2.01)  1.69 (1.42─2.01) 
Adm Killip class II–IV n = 1119 1.93 (1.63─2.29) 1.80 (1.52─2.14)  1.73 (1.46─2.05)  1.66 (1.39─1.96) 
Max Killip class II–IV n = 1119 1.93 (1.63─2.29) 1.69 (1.42─2.00)  1.73 (1.46─2.05)  1.58 (1.32─1.87) 
Thrombolysis n = 1121 1.93 (1.63─2.28) 1.94 (1.64─2.30)  1.73 (1.46─2.05)  1.77 (1.49─2.10) 
Primary PCI n = 1121 1.93 (1.63─2.28) 1.96 (1.36─2.32)  1.73 (1.46─2.05)  1.73 (1.36─2.05) 
Other PCI n = 1121 1.93 (1.63─2.28) 1.88 (1.59─2.23)  1.73 (1.46─2.05)  1.71 (1.44─2.03) 
CABG n = 1121 1.93 (1.63─2.28) 1.93 (1.63─2.28)  1.73 (1.46─2.05)  1.72 (1.45─2.04) 
No thrombolysis/revasc n = 1121 1.93 (1.63─2.28) 1.94 (1.64─2.30)  1.73 (1.46─2.05)  1.74 (1.47─2.06) 
LVEF n = 879 1.89 (1.56─2.29) 1.64 (1.35─2.00)  1.80 (1.48─2.18)  1.64 (1.35─1.99) 
GRACE risk score n = 1118 1.92 (1.63─2.28) 1.55 (1.30─1.84)  1.72 (1.46─2.04)  1.56 (1.31─1.85) 
_______________________________________________________________________________________ 
Hazard ratios with corresponding 95% confidence intervals. Variables significantly affecting the hazard ratio by >3% are shown 
in bold. 
Abbreviations: MI─myocardial infarction; HF─heart failure; STEMI─ST-elevation MI; NSTEMI─non STEMI; Adm─admission; 
TnT─troponin T; GFR─glomerular filtration rate; BNP─brain natriuretic peptide; hsCRP─high sensitivity C-reactive protein; 
LDL─low-density lipoprotein; BMI─body mass index; PCI percutaneous coronary intervention; CABG─coronary artery bypass 
grafting; LVEF─left ventricular ejection fraction; GRACE─Global Registry of Acute Coronary Events. 




Multivariable analyses of the relationship between NGAL q4 vs q1–3 and all-cause long-term mortality 
adjusted for the variables in Table 1 with anearly complete data and for ball variables. 
aAdjusted   
  N = 1086 Hazard 95% Confidence limits P-value 
Parameter ratio Lower Upper 
 NGAL q4 vs. q1–3 1.333 1.1 1.614 0.0033 
Age 1.078 1.064 1.093 <.0001 
Sex 0.831 0.689 1.001 0.0518 
Previous MI 1.696 1.37 2.099 <.0001 
Previous angina 1.182 0.984 1.42 0.0734 
Previous HF 1.589 1.197 2.11 0.0014 
Previous diabetes 1.61 1.316 1.97 <.0001 
Current smoker 1.404 1.161 1.697 0.0005 
Lipid-lowering drug  1.009 0.79 1.289 0.9428 
SBP <100 at admission 1.675 1.047 2.678 0.0313 
ln(eGFR) 0.637 0.45 0.902 0.0111 
Max Killip II–IV 1.76 1.437 2.156 <.0001 
Thrombolysis 0.861 0.686 1.081 0.1978 
Primary PCI 0.892 0.67 1.186 0.4308 
Other PCI 0.88 0.702 1.103 0.2671 
     bAdjusted  
    N = 639 Hazard  95% Confidence limits P-value 
Parameter ratio Lower             Upper  
 
 
NGAL q4 vs. q123 1.497 1.158 1.935 0.002 
Age 1.073 1.053 1.094 <.0001 
Sex 0.934 0.72 1.211 0.6064 
Previous MI 1.371 1.022 1.838 0.0351 
Previous angina 1.417 1.106 1.817 0.0059 
Previous HF 1.522 1.025 2.26 0.0371 
Previous diabetes 1.568 1.19 2.067 0.0014 
Current smoker 1.448 1.117 1.877 0.0051 
Lipid-lowering drug 0.843 0.59 1.205 0.3499 
SBP <100 at admission 2.305 1.226 4.336 0.0095 
ln(estimated GFR) 0.645 0.405 1.026 0.0643 
Max Killip II–IV 1.305 0.978 1.742 0.0705 
Thrombolysis 0.867 0.641 1.171 0.3522 
Primary PCI 0.753 0.53 1.069 0.1126 
Other PCI 0.793 0.591 1.065 0.1239 
ln(proBNP) 1.013 0.884 1.161 0.8495 
hsCRP 1.001 0.998 1.005 0.4909 
total cholesterol 1.059 0.829 1.353 0.6471 
ln(LDL cholesterol) 0.493 0.204 1.191 0.116 
LVEF 0.973 0.962 0.985 <0.0001 
     




Interactions between NGAL concentration and extended long-term mortality. 
_______________________________________________________________________________________ 
    P for 
 N NGAL q1–3 NGAL q4  interaction 
_______________________________________________________________________________________ 
           
Age >73 years (q4) a841/280 b3.40 (2.77─4.18) b 3.06 (2.29─4.08) 0.66 
 
Sex 841/280 1.10 (0.90─1.35) 1.21 (0.88─1.65) 0.63 
 age adjusted  0.82 (0.67─1.02) 1.07 (0.78─1.46) 0.20 
 
Previous MI 841/280 2.08 (1.68─2.57) 2.16 (1.59─2.93) 0.74 
 age adjusted  2.00 (1.62─2.48) 2.09 (1.54─2.85) 0.75 
 
Previous angina 841/280 1.58 (1.30─1.92) 1.86 (1.40─2.45) 0.34 
age adjusted  1.38 (1.14─1.68) 1.50 (1.13─1.98) 0.74 
 
Previous HF 841/280 3.03 (2.20─4.16) 2.96 (1.99─4.40) 0.92 
 age adjusted  2.71 (1.97─3.73) 2.29 (1.54─3.40) 0.53 
 
Previous diabetes 841/280 1.80 (1.42─2.28) 1.64 (1.19─2.27) 0.67 
 age adjusted  1.78 (1.40─2.26) 1.62 (1.17─2.23) 0.64 
 
Previous hypertension 841/279 1.47 (1.21─1.78) 1.47 (1.11─1.94) 0.91 
 age adjusted  1.29 (1.06─1.57) 1.37 (1.04─1.80) 0.67 
 
Previous hypercholesterolaemia 840/280 0.95 (0.77─1.18) 1.05 (0.76─1.45) 0.57 
 age adjusted  1.13 (0.91─1.39) 1.19 (0.86─1.65) 0.64 
 
Current smoker 829/274 0.70 (0.55─0.88) 0.90 (0.68─1.21) 0.16 
 age adjusted  1.20 (0.95─1.52) 1.20 (0.89─1.62) 0.77 
 
Lipid-lowering drug 841/280 1.34 (1.04─1.73) 1.27 (0.83─1.95) 0.91 
 age adjusted  1.50 (1.16─1.94) 1.25 (0.82─1.92) 0.58 
 
STEMI 841/280 0.94 (0.77─1.14) 0.79 (0.60─1.04) 0.36 
 age adjusted  0.99 (0.81─1.20) 0.77 (0.58─1.02) 0.18 
 
NSTEMI 841/280 1.06 (0.87─1.30) 1.28 (0.96─1.71) 0.33 
 age adjusted  1.06 (0.86─1.30) 1.32 (0.99─1.76) 0.25 
 
ST elevation at admission 839/280 0.86 (0.70─1.06) 0.82 (0.62─1.09) 0.83 
 age adjusted  0.92 (0.75─1.13) 0.82 (0.62─1.09) 0.56 
 
ST depression at admission 839/280 1.71 (1.30─2.26) 1.78 (1.23─2.56) 0.81 
 age adjusted  1.56 (1.18─2.06) 1.58 (1.10─2.28) 0.96 
 
Q-wave at admission 839/280 1.11 (0.80─1.52) 1.26 (0.88─1.79) 0.53 
 age adjusted  1.12 (0.82─1.55) 1.19 (0.83─1.69) 0.74 
 
Systolic BP <100 at admission 841/280 1.40 (0.77─2.55) 0.99 (0.51─1.94) 0.45 
 age adjusted  1.99 (1.09─3.65) 1.26 (0.64─2.45) 0.36 
 
Heart rate at admission 840/280  
 HR >86 (q4)  1.65 (1.33─2.04) 1.38 (1.02─1.86) 0.42 
 HR >86 (q4) age adjusted  1.76 (1.42─2.19) 1.56 (1.15─2.11) 0.60 




CK-MB max 841/280  
 CK-MB >184 (q4)  1.05 (0.83─1.32) 0.90 (0.67─1.22) 0.43 
 CK-MB >184 (q4) age adjusted  1.16 (0.92─1.46) 0.98 (0.73─1.33) 0.42 
 
TnT max 706/225  
 TnT >3.8 (q4)  1.14 (0.88─1.46) 0.94 (0.68─1.31) 0.35 
 TnT >3.8 (q4) age adjusted  1.03 (0.80─1.32) 0.97 (0.70─1.34) 0.78 
 
Ln (TnI) at admission 616/185  
 TnI >16.8 (q4)  1.01 (0.78─1.32) 1.00 (0.68─1.46) 0.96 
 TnI >16.8 (q4) age adjusted  1.07 (0.82─1.40) 1.25 (0.85─1.83) 0.41 
 
Ln (Estimated GFR) 829/275  
 eGFR <52 (q1)  2.22 (1.78─2.78) 3.00 (2.26─4.00) 0.11 
 eGFR <52 (q1) age adjusted  1.01 (0.79─1.28) 1.68 (1.20─2.34) 0.13 
 
Ln (ProBNP) 718/210  
 proBNP >3231 (q4)  2.33 (1.86─2.92) 2.27 (1.64─3.15) 0.96 
 proBNP >3231 (q4) age adjusted  1.61 (1.28─2.03) 1.55 (1.11─2.16) 0.88 
 
hsCRP 733/208  
 hsCRP >36.5 (q4)  1.47 (1.16─1.88) 1.36 (0.98─1.87) 0.75 
 hsCRP >36.5 (q4) age adjusted  1.47 (1.16─1.88) 1.04 (0.75─1.44) 0.12 
 
Leukocytes 808/271  
 leukocytes >11.1 (q4)  0.97 (0.76─1.24) 1.45 (1.08─1.93) 0.03 
 leukocytes >11.1 (q4) age adjusted  1.31 (1.02─1.68) 1.70 (1.27─2.27) 0.12 
 
Total cholesterol 802/261  
 total cholesterol <4.6 (q1)  1.56 (1.23─1.98) 1.48 (1.10─2.00) 0.86 
 total cholesterol <4.6 (q1) age adjusted  1.37 (1.08─1.73) 1.35 (1.00─1.82) 0.93 
 
Ln (LDL cholesterol) 720/236  
 LDL <2.77 (q1)  1.40 (1.10─1.78) 1.50 (1.10─2.04) 0.69 
 LDL <2.77 (q1) age adjusted  1.38 (1.09─1.76) 1.50 (1.09─2.04) 0.69 
 
BMI 824/268  
 BMI <20 or >30  1.20 (0.95─1.52) 1.02 (0.68─1.52) 0.49 
 BMI <20 or >30 age adjusted  1.27 (1.00─1.60) 1.09 (0.73─1.63) 0.57 
 
Killip class II–IV at admission 839/280 3.76 (2.61─5.41) 2.09 (1.38─3.16) <0.05 
  age adjusted  2.43 (1.68─3.52) 1.53 (1.00─2.32) 0.06 
Max Killip class II–IV 839/280 3.01 (2.38─3.82) 1.92 (1.43─2.57) 0.03 
 age adjusted  2.20 (1.73─2.80) 1.45 (1.07─1.96) 0.02 
 
Thrombolysis 841/280 1.10 (0.86─1.42) 0.76 (0.54─1.06) 0.07 
 age adjusted  1.00 (0.77─1.29) 0.62 (0.44─0.88) 0.02 
 
Primary PCI 841/280 0.65 (0.48─0.89) 0.51 (0.33─0.79) 0.39 
 age adjusted  0.88 (0.64─1.20) 0.74 (0.47─1.14) 0.72 
 
Other PCI 841/280 0.69 (0.53─0.89) 0.88 (0.58─1.33) 0.29 
 age adjusted  0.83 (0.64─1.07) 0.98 (0.65─1.49) 0.39 
 
CABG 841/280 0.93 (0.66─1.29) 1.01 (0.62─1.66) 0.75 
 age adjusted  0.82 (0.59─1.15) 1.02 (0.62─1.68) 0.48 
 
No thrombolysis/ 
revascularization 841/280 1.45 (1.19─1.76) 1.69 (1.28─2.23) 0.38 
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 age adjusted  1.23 (1.01─1.50) 1.52 (1.15─2.01) 0.30 
 
LVEF 661/218  
 LVEF <45 (q1)  2.92 (2.30─3.72) 1.80 (1.31─2.49) 0.02 
 LVEF <45 (q1) age adjusted  2.33 (1.82─2.98) 1.65 (1.20─2.29) 0.09 
 
GRACE risk score 838/280  
 GRACE >127 (q4)  3.92 (3.19─4.83) 3.14 (2.37─4.17) 0.26 
 GRACE >127 (q4) age adjusted  2.01 (1.60─2.52) 1.79 (1.30─2.46) 0.23 
________________________________________________________________________________________________ 
aNumber in q1─3/q4.  
bHazard ratios with corresponding 95% confidence interval. 





Comparison of hazard ratios (HR) and 95% confidence intervals (CI) between 938 patients with data for 
NGAL and CRP concentrations─and GRACE score. 
 
 









NGAL q1–3/GRACE q1–3 583 1   
NGAL q4/GRACE q1–3  136 1.92 1.49–2.46 <0.0001 
NGAL q1–3/GRACE q4  147 3.77 3.01–4.73 <0.0001 




    hsCRP and GRACE N HR 95% CI P-value 
hsCRP q1–3/GRACE q1–3 558 1 
  hsCRP q4/GRACE q1–3 161 1.53 1.20–1.96 0.0007 
hsCRP q1–3/GRACE q4 147 4.04 3.23–5.06 <0.0001 




    NGAL and hsCRP N HR 95% CI P-value 
NGAL q1–3/hsCRP q1–3 578 1 
  NGAL q4/hsCRP q1–3 127 2.06 1.62–2.63 <0.0001 
NGAL q1–3/hsCRP q4 152 1.5 1.18–1.92 0.001 
NGAL q4/hsCRP q4 81 2.8 2.13–3.67 <0.0001 
 
